Management provided Q4 revenue guidance in the range of $650 million to $710 million, reflecting backlog strength and anticipated sequential growth. Hider noted that transportation revenues are ...

Seeing “growth on hiatus,” Mr. Bir reduced his own forecast for 2025 and 2026 “with revisions mainly for longer lease-up ...

The Canadian automation and technology company said U.S. tariffs on Canadian imports will add complexity in the short ...

After a fourth-quarter earnings miss and “subpar” outlook, National Bank Financial analyst Maxim Sytchev warns investors 2025 ...

Investing.com -- TD Cowen analysts view Sen. Dan Sullivan’s proposed missile defense legislation as a long-term catalyst for major U.S. defense contractors, with Lockheed Martin (NYSE ...

Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry ...

TD Cowen analyst Ryan Langston maintained a Buy rating on Molina Healthcare (MOH – Research Report) today and set a price target of $378.00. The company’s shares closed yesterday at $317.01.

TD Cowen analyst Daniel Brennan maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today and set a price target of $118.00. The company’s shares closed yesterday at $67.18.